Batavia Bioservices and Xendo Announce Business Collaboration

LEIDEN, NETHERLANDS--(Marketwire - August 26, 2011) - Today Batavia Bioservices BV and Xendo BV announce that they have initiated a strategic business collaboration. As a consequence, all Bioprocess activities of Xendo Manufacturing BV have been transferred to Batavia Bioservices BV. This provides Batavia Bioservices BV access to unique simulated moving bed (SMB) purification technology as well as infrastructure, knowledge and experience in microbial process and product development. At the same time, the companies will establish joint marketing efforts whereby Xendo BV will provide engineering, regulatory and clinical support services and Batavia Bioservices will provide process development and analytical services.

Menzo Havenga (CEO, Batavia Bioservices BV) explains: Xendo BV and Batavia Bioservices BV together have more critical mass and therefore are able to execute larger, more complex customer programs. It is fully expected that our collaboration will result in more customers being offered a complete development services package. André van de Sande, CEO Xendo BV, adds: I trust that by combining our forces both companies are better positioned to service our customers. This helps Xendo BV, both in the Netherlands and international, to further expand.

Information on Xendo BV

Xendo is a leading, independent consultancy and project management organization in the life sciences, pharmaceutical and healthcare fields. Our ambition is to enhance the quality and safety of medicine and help shorten the time to market for drugs and medical devices that improve the quality of life. Xendo was established in 1990 (originally under the name of Univalid) and is fully privately owned.

Xendo has offices in Leiden (headquarter) and in Berlin. The company employs close to a hundred employees and has its own in-house QA and Knowledge management center and is ISO 9001 certified.

More information on Xendo can be found on

Information on Batavia Bioservices BV:

Batavia Bioservices is a biopharmaceutical process development services Company dedicated to add value to customers by providing high quality biopharmaceuticals for proof-of -concept and pre-clinical product development studies. The company focuses on the early stages of product development with services ranging for DNA cloning and mammalian cell line generation, to upstream process development, purification and product characterization. Headquartered in Leiden, The Netherlands, Batavia Bioservices is privileged to have strong strategic partners in both the Netherlands and the United States of America. Batavia Bioservices is a limited liability company that is not publicly traded. More information on Batavia Bioservices can be found on

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Batavia Bioservices B.V. via Thomson Reuters ONE


For more information about this press release:
Menzo Havenga
CEO Batavia Bioservices B.V.
Email Contact
+31 888 669642

Back to news